“In this research perspective, we discuss recent work from our lab describing an active role of HSPCs in AML and the potential implications.”
BUFFALO, NY- September 5, 2024 – A new research perspective was published in Oncotarget’s Volume 15 on September 4, 2024, entitled, “Trained and ready – the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche.”
As noted in the abstract of this paper, lifelong hematopoiesis is sustained by the crosstalk between hematopoietic stem and progenitor cells (HSPCs) and specialized bone marrow niches. Acute myeloid leukemia (AML) disrupts this balance, as leukemic blasts secrete factors that remodel the bone marrow into a self-reinforcing leukemic niche. Additionally, HSPCs are key components of the innate immune system. Over the past decade, elegant studies of infection and experimental inflammation have demonstrated the generation of an adoptively transferable, innate immune memory.
In their research perspective, Ding-Wen Chen, Eric K. Wafula, and Peter Kurre from the Department of Pediatrics, Comprehensive Bone Marrow Failure Center, Division of Hematology and the Department of Biomedical and Health Informatics at the Children’s Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, discuss recent findings from their lab on the active role of HSPCs in AML and its potential implications.
“Considering the abundant evidence for AML associated inflammation, and the involvement of healthy HSPCs discussed in our study, the question arises whether sterile cancer-associated inflammation also has long-term functional consequences.”
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28642
Correspondence to: Ding-Wen Chen – chend5@chop.edu, and Peter Kurre – kurrep@chop.edu
Keywords: cancer, hematopoietic stem and progenitor cells, acute myeloid leukemia, inflammation, innate immune reprogramming, trained immunity
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.